118811-07-7

Basic information

• Product Name: 4-(TOLUENE-4-SULFONYLOXY)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER
• Synonyms: N-BOC-4-TOXYLOXY-PIPERIDINE;4-(Toluene-4-sulfonyloxy)piperidine-1-carboxylic acid tert-butyl ester;1-Boc-4-(tosyloxy)piperidine;(1-BOC-piperidin-4-yl)tosylate;t-Butyl 4-(tosyloxy)piperidine-1-carboxylate;tert-butyl 4-(tosyloxy)piperidine-1-carboxylate;1-Piperidinecarboxylic acid, 4-[[(4-methylphenyl)sulfonyl]oxy]-, 1,1-dimethylethyl ester;1-(tert-Butoxycarbonyl)-4-(p-toluenesulfonyloxy)piperidine
• CAS NO: 118811-07-7
• Molecular Formula: C₁₇H₂₅NO₅S
• Molecular Weight: 355.45
• Mol File: 118811-07-7.mol
• Article Data: 41

Chemical Properties

• Melting Point: 96.0 to 100.0 °C
• Boiling Point: 475.282 °C at 760 mmHg
• Flash Point: 241.242 °C
• Appearance: /
• Density: 1.237 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.553
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• Solubility: soluble in Methanol
• PKA: -2.97±0.40(Predicted)
• CAS DataBase Reference: 4-(TOLUENE-4-SULFONYLOXY)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(TOLUENE-4-SULFONYLOXY)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(118811-07-7)
• EPA Substance Registry System: 4-(TOLUENE-4-SULFONYLOXY)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(118811-07-7)

Safety Data

• Hazardous Substances Data: 118811-07-7(Hazardous Substances Data)

Usage

General Description

4-(Toluene-4-sulfonyloxy)-piperidine-1-carboxylic acid tert-butyl ester is a chemical compound that falls under the category of piperidine derivatives. It contains a piperidine ring with a tert-butyl ester group and a toluene-4-sulfonyloxy group attached to it. 4-(TOLUENE-4-SULFONYLOXY)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER is often used in organic synthesis and pharmaceutical research as a building block for the synthesis of various bioactive molecules. Its unique structure and reactivity make it valuable for drug discovery and development, particularly in the creation of novel therapeutic agents for a wide range of medical conditions.

InChI:InChI=1/C17H25NO5S/c1-13-5-7-15(8-6-13)24(20,21)23-14-9-11-18(12-10-14)16(19)22-17(2,3)4/h5-8,14H,9-12H2,1-4H3

Upstream product

• 98-59-9 p-toluenesulfonyl chloride 
• 123855-51-6 tert-butyl 4-(hydroxymethyl)piperidin-1-carboxylate 
• 5382-16-1 4-HYDROXYPIPERIDINE 
• 24424-99-5 di-tert-butyl dicarbonate 
• 86953-81-3 tert-butyl 2-hydroxypiperidine-1-carboxylate 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 5382-30-9 1-(1,1-dimethylethyl)-4-piperidinol 

Downstream Products

• 141699-66-3 1-tert-Butyloxycarbonyl-4-(acetylsulfanyl)piperidine 
• 1154415-24-3 C₁₈H₂₄ClNO₅ 
• 1154415-30-1 tert-butyl 4-[2-chloro-5-methoxy-4-(methoxycarbonyl)phenoxy]piperidine-1-carboxylate 
• 1154415-46-9 C₁₉H₂₇NO₅ 
• 1154411-46-7 C₃₁H₃₇Cl₃N₄O₆ 
• 949464-89-5 methyl 1-(1-{[(1,1-dimethylethyl)oxy]carbonyl}-4-piperidinyl)-6-phenyl-1H-indazole-4-carboxylate 
• 1612155-93-7 tert-butyl 4-(4-acetamidophenyl)piperidine-1-carboxylate 
• 183950-95-0 tert-butyl 4-(4'-fluorophenyl)piperidine-1-carboxylate 
• 201609-29-2 1-t-Butoxycarbonyl-4-(2-methoxyphenyl)piperidine 

Relevant articles and documents

Discovery and optimization of a potent and selective indazolamine series of IRAK4 inhibitors

IRAK4 is a key mediator of innate immunity. There is a high interest in identifying novel IRAK4 inhibitors for the treatment of inflammatory autoimmune diseases. We describe here a highly potent and selective IRAK4 inhibitor (HS271) that exhibited superio

Design, synthesis and biological evaluation of 2-substituted-6-[(4-substituted-1-piperidyl)methyl]-1H-benzimidazoles as inhibitors of ebola virus infection

Novel 2-substituted-6-[(4-substituted-1-piperidyl)methyl]-1H-benzimidazoles were designed and synthesized as Ebola virus inhibitors. The proposed structures of the new prepared benzimidazole-piperidine hybrids were confirmed based on their spectral data and CHN analyses. The target compounds were screened in vitro for their anti-Ebola activity. Among tested molecules, compounds 26a (EC50=0.93 μM, SI = 10) and 25a (EC50=0.64 μM, SI = 20) were as potent as and more selective than Toremifene reference drug (EC50 = 0.38 μM, SI = 7) against cell line. Data suggests that the mechanism by which 25a and 26a block EBOV infection is through the inhibition of viral entry at the level of NPC1. Furthermore, a docking study revealed that several of the NPC1 amino acids that participate in binding to GP are involved in the binding of the most active compounds 25a and 26a. Finally, in silico ADME prediction indicates that 26a is an idealy drug-like candidate. Our results could enable the development of small molecule drug capable of inhibiting Ebola virus, especially at the viral entry step.

8-substituted styryl xanthine derivative and application thereof

The invention discloses an 8-substituted styryl xanthine derivative and application thereof, and particularly relates to a novel 8-substituted styryl xanthine derivative and a pharmaceutical composition containing the compound which can be used as a selective adenosine A2A receptor antagonist. The invention also relates to a method for preparing the compound and the pharmaceutical composition, andapplication of the compound and the pharmaceutical composition in preparation of drugs for treating adenosine A2A receptor related diseases, especially Parkinson's disease.